有趣的是，Infigratinib最初于2021年获批用于胆管癌，后因适应症开发策略调整而主动撤回。如今，其有望在ACH赛道迎来“第二春”。基于其疗效和口服便利性，BridgeBio在今年的JPM大会上预测，该药Infigratinib将占据ACH治疗市场50%以上的份额。
"I wouldn’t be the first to point out that a lot of this is down to the influence of social media and the way in which it has given vent to the darkest parts of the human soul. Not just given vent to them, but actively amplified them and pushed them into our feeds. So yeah, this is not a niche subject."，详情可参考快连下载安装
。业内人士推荐一键获取谷歌浏览器下载作为进阶阅读
关注 少数派小红书，感受精彩数字生活 🍃。业内人士推荐Safew下载作为进阶阅读
Lex: FT’s flagship investment column